var data={"title":"Cladribine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cladribine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5912?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">see &quot;Cladribine: Drug information&quot;</a> and <a href=\"topic.htm?path=cladribine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cladribine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708674\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Cladribine should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Acute nephrotoxicity has been observed with high doses of cladribine (4 to 9 times the recommended dose for hairy cell leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28104203\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cladribine Injection;</li>\n      <li>Mavenclad</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046381\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Analog)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046375\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">see &quot;Cladribine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents (details concerning dosing in combination regimens and protocols should be consulted):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Acute myeloid leukemia:</b> Limited data available: IV: 8.9 mg/m<sup>2</sup>/day continuous infusion for 5 days for 1 or 2 courses (Krance, 2001) or 9 mg/m<sup>2</sup>/day over 30 minutes for 5 days for 1 course (in combination with cytarabine) (Crews, 2002; Rubnitz, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Langerhans cell histiocytosis, refractory:</b> Limited data available: IV: 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 21 days for up to 6 cycles (Weitzman, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: Details concerning dosing in combination regimens should also be consulted. <b>Hairy cell leukemia:</b> IV: 0.09 mg/kg/day continuous infusion for 7 days for 1 cycle </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (due to inadequate data); use with caution. The following guidelines have been used by some clinicians (Aronoff, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR 10-50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis: Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10-50 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (due to inadequate data); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152263\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/10 mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152250\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046385\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: Further dilute prior to use, may be administered over 24 hours as a continuous infusion, or as an intermittent infusion over 30 minutes or 2 hours; dependent upon indication and/or protocol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130932\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).    </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152278\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. A precipitate may develop at low temperatures and may be resolubilized at room temperature or by shaking the solution vigorously. Inadvertent freezing does not affect the solution; if freezing occurs prior to dilution, allow to thaw naturally prior to reconstitution; do not heat or microwave; do not refreeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solutions for infusion diluted in NS in PVC containers are stable for 24 hours at room temperature and normal lighting conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">24-hour continuous infusion: Dilutions in NS for infusion should be used promptly; if not used promptly, the 24-hour infusion may be stored refrigerated for up to 8 hours prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">7-day continuous infusion: Dilutions in NS for infusion should be used promptly; if not used promptly, the 7-day infusion may be stored refrigerated for up to 8 hours prior to administration. Reconstituted solution is stable for 7 days (when diluted in bacteriostatic NS) in a CADD medication cassette reservoir. For patients weighing &gt;85 kg, the effectiveness of the preservative in the bacteriostatic diluent may be reduced (due to dilution).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture. Store in original packing until immediately before use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046384\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of active hairy cell leukemia (FDA approved in adults); has also been used for acute myeloid leukemia and refractory Langerhans cell histiocytosis (LCH) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152326\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cladribine may be confused with clevidipine, clofarabine, cytarabine, fludarabine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leustatin may be confused with lovastatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152324\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema, phlebitis, tachycardia, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety, chills, dizziness, fatigue, headache, insomnia, malaise, myasthenia, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis, erythema, hyperhidrosis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (recovery by week 8), bone marrow depression (prolonged), bruise, febrile neutropenia (less common in severe), neutropenia (grade 4; recovery by week 5), petechia, purpura, thrombocytopenia (grade 4; recovery by day 12)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Abnormal breath sounds, cough, dyspnea, epistaxis, rales</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Aplastic anemia, bacteremia, cellulitis, cerebrovascular accident, conjunctivitis, decreased CD-4 cell count (nadir: 4 to 6 months), eosinophilia (hypereosinophilia or persistent), hemolytic anemia, hypersensitivity reaction, impaired consciousness, lower extremity weakness, myelodysplastic syndrome, opportunistic infection (cytomegalovirus disease, fungal infection, herpes virus infection, listeriosis, <i>Pneumocystis jirovecii</i>), paresis (at high doses; paraparesis/quadriparesis), pneumonia, polyneuropathy (with high doses), progressive multifocal leukoencephalopathy, pulmonary infiltrates (interstitial), reactivated tuberculosis, renal failure, renal insufficiency (with high doses), septic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152269\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cladribine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]: Hypersensitivity to cladribine or any component of the formulation; patients at increased risk of opportunistic infections (including those immunocompromised due to therapy [immunosuppressive or immunomodulating, antineoplastic or myelosuppressive therapies; total lymphoid irradiation; bone marrow transplantation] or disease [immunodeficiency syndrome]); latent or active infections (including active chronic bacterial, fungal or viral infections [eg, hepatitis, tuberculosis]); history of progressive multifocal leukoencephalopathy; active malignancy; moderate or severe renal impairment (CrCL &lt;60 mL/minute); pregnancy; breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152254\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Dose-dependent myelosuppression (neutropenia, anemia, and thrombocytopenia) is common and generally reversible.</b> Use with caution in patients with preexisting hematologic or immunologic abnormalities. Monitor blood counts, especially during the first 4 to 8 weeks after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fever: Treatment is associated with fever (&ge;100&deg;F), with or without neutropenia, and is observed more commonly in the first month of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Infections (bacterial, viral, and fungal) were reported more commonly in the first month after treatment (generally mild or moderate in severity, although serious infections including sepsis have been reported); the incidence is reduced in the second month. Due to neutropenia and T-cell depletion, risk versus benefit of treatment should be evaluated in patients with active infections. If active infection is present, manage appropriately prior to administering cladribine (Grever 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: Serious, dose-related neurologic toxicity (including irreversible paraparesis and quadriparesis) has been reported with continuous infusions of higher doses (4 to 9 times the approved dose); may also occur at approved doses (rare).</b> Neurotoxicity may be delayed and may present as progressive, irreversible motor weakness of the upper and/or lower extremities; diagnostics with electromyography and nerve conduction studies were consistent with demyelinating disease. Neurotoxicity after high-dose administration was first noted 35 to 84 days after therapy initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: <b>[US Boxed Warning]: Acute nephrotoxicity (eg, acidosis, anuria, increased serum creatinine), possibly requiring dialysis, has been reported with high doses (4 to 9 times the approved dose), particularly when administered with other nephrotoxic agents.</b> Per the manufacturer, nephrotoxicity has not occurred when used at the dose approved for hairy cell leukemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: With high tumor burden, tumor lysis syndrome and subsequent hyperuricemia may occur (rare); consider antihyperuricemics and hydrate accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Weekly (7-day) infusion preparation recommends further dilution with bacteriostatic normal saline which contains benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral tablet [Canadian product]: Multiple sclerosis: Use is contraindicated in patients with active or latent tuberculosis. Complete immunizations at least 6 weeks prior to treatment initiation. Evaluate hepatitis B and C status prior to treatment. Assess varicella zoster virus (VZV) antibody status prior to treatment; if no confirmed history of chicken pox or vaccination and VZV antibody is negative, vaccination is recommended (delay cladribine for 6 weeks after vaccination). Only initiate treatment if lymphocyte counts are normal, Obtain a baseline MRI if patient has previously received MS therapy associated with progressive multifocal leukoencephalopathy (PML); do not initiate or re-initiate therapy until PML has been excluded. May be associated with an increased risk of malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Administration of live vaccines is not recommended during treatment with cladribine (may increase the risk of infection due to immunosuppression).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299054\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219339\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13164&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152259\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3016299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of reproductive potential should use highly effective contraception during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oral tablet [Canadian product]: Use is contraindicated in pregnancy. Exclude pregnancy prior to treatment. Females of reproductive potential and males with female partners of reproductive potential should use effective contraception during treatment and for 6 months after the final cladribine dose. Women who become pregnant during therapy should discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046380\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (particularly during the first 4-8 weeks post-treatment); baseline and periodic renal and hepatic function tests; body temperature (fever); bone marrow biopsy (after CBC has normalized; to confirm treatment response); signs and symptoms of neurotoxicity </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152253\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cladribine is a purine nucleoside analogue; it is a prodrug which is activated via phosphorylation by deoxycytidine kinase to a 5'-triphosphate derivative (2-CaAMP). This active form incorporates into DNA to result in the breakage of DNA strand and shutdown of DNA synthesis and repair. This also results in a depletion of nicotinamide adenine dinucleotide and adenosine triphosphate (ATP). Cladribine is cell-cycle nonspecific.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152268\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 8 months to 18 years: 12.7 &plusmn; 8.5 L/kg; penetrates CSF (CSF concentrations are ~18% of plasma concentration) (Kearns 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~9 L/kg; penetrates CSF (CSF concentrations are ~25% of plasma concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 8 months to 18 years: 19.7 &plusmn; 3.4 hours (Kearns 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: After a 2-hour infusion (with normal renal function): 5.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Absorption: Rapid; delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bioavailability: ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Half-life elimination: ~24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Time to peak: 30 to 90 minutes (fasting); 1 to 3 hours (with high-fat meal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323071\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cladribine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $420.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038562\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ai Bo Ding (CN);</li>\n      <li>Biodribin (PL);</li>\n      <li>Cladrim (IN);</li>\n      <li>Intocel (AR);</li>\n      <li>Kitak (RO);</li>\n      <li>Leustat (AR, GB, IE);</li>\n      <li>Leustatin (AT, AU, BE, BG, BR, CH, CR, DO, ES, FI, GR, GT, HK, HN, IT, KR, LU, NI, NL, NZ, PA, PH, PT, SE, SG, SV, TW, UY, VE);</li>\n      <li>Leustatine (FR);</li>\n      <li>Litak (AE, AT, AU, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IL, IT, JO, LB, LT, LV, MT, NL, NO, PL, PT, RU, SE, SI, SK, TR, TW);</li>\n      <li>Mavenclad (CZ);</li>\n      <li>Plane (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crews KR, Gandhi V, Srivastava DK, et al, &ldquo;Interim Comparison of a Continuous Infusion versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia,&rdquo; <i>J Clin Oncol</i>, 2002, 20(20):4217-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/12377965/pubmed\" target=\"_blank\" id=\"12377965\">12377965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns CM, Biakley RL, Santane VM, et al, &ldquo;Pharmacokinetics of Cladribine (2-Chlorodeoxyadenosine) in Children with Acute Leukemia,&rdquo; <i>Cancer Research</i>, 1994, 54:1235-39. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/7906999 /pubmed\" target=\"_blank\" id=\"7906999 \">7906999 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krance RA, Hurwitz CA, Head DR, et al, &ldquo;Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases,&rdquo; <i>J Clin Oncol</i>, 2001, 19(11):2804-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/11387351/pubmed\" target=\"_blank\" id=\"11387351\">11387351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, et al, &ldquo;Dose Escalation Trial of Cladribine Using 5 Daily I.V. Infusions in Patients with Advanced Hematologic Malignancies,&rdquo; <i>J Clin Oncol</i>, 1996, 14(1):188-95. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/8558197/pubmed\" target=\"_blank\" id=\"8558197\">8558197</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liliemark J, &ldquo;The Clinical Pharmacokinetics of Cladribine,&rdquo; <i>Clin Pharmacokinet</i>, 1997, 32:120-131. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/9068927/pubmed\" target=\"_blank\" id=\"9068927\">9068927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez-Galindo C, Kelly P, Jeng M, et al, &ldquo;Treatment of Children With Langerhans Cell Histiocytosis With 2-Chlorodeoxyadenosine,&rdquo; <i>Am J Hematol</i>, 2002, 69(3):179-84. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/11891804 /pubmed\" target=\"_blank\" id=\"11891804 \">11891804 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubnitz JE, Crews KR, Pounds S, et al, &ldquo;Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St Jude AML97 Trial,&rdquo; <i>Leukemia</i>, 2009, 23(8):1410-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/19242495/pubmed\" target=\"_blank\" id=\"19242495\">19242495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stine KC, Saylors RL, Williams LL, et al, &ldquo;2-Chlorodeoxyadenosine (2-CDA) for the Treatment of Refractory or Recurrent Langerhans Cell Histiocytosis (LCH) in Pediatric Patients,&rdquo; <i>Med Pediatr Oncol</i>, 1997, 29:288-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/9251735/pubmed\" target=\"_blank\" id=\"9251735\">9251735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weitzman S, Braier J, Donadieu J, et al, &ldquo;2'-Chlorodeoxyadenosine (2-CdA) as Salvage Therapy for Langerhans Cell Histiocytosis (LCH). Results of the LCH-S-98 Protocol of the Histiocyte Society,&rdquo; <i>Pediatr Blood Cancer</i>, 2009, 53(7):1271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-pediatric-drug-information/abstract-text/19731321/pubmed\" target=\"_blank\" id=\"19731321\">19731321</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13164 Version 136.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708674\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28104203\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046381\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046375\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F152263\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F152250\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046385\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130932\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F152278\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046384\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F152326\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F152324\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152269\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152254\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299054\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219339\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F152259\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3016299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046380\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152253\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F152268\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323071\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038562\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13164|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">Cladribine: Drug information</a></li><li><a href=\"topic.htm?path=cladribine-patient-drug-information\" class=\"drug drug_patient\">Cladribine: Patient drug information</a></li></ul></div></div>","javascript":null}